Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population by Jiang, Ju-Hong et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Genetic polymorphisms of CYP2A13 and its relationship to 
nasopharyngeal carcinoma in the Cantonese population
Ju-Hong Jiang1, Wei-Hua Jia1, Han-Kui Chen1, Bing-Jian Feng1, Hai-De Qin1, 
Zhi-Gang Pan1, Guo-Ping Shen1, Li-Xi Huang1, Qi-Sheng Feng1, Li-
Zhen Chen1, Dong-Xin Lin2 and Yi-Xin Zeng*1
Address: 1Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou and 2Cancer Institute, Chinese Academy of 
Medical Science, Beijing, China
Email: Ju-Hong Jiang - pj45@gzsums.edu.cn; Wei-Hua Jia - pj45@gzsums.edu.cn; Han-Kui Chen - pj45@gzsums.edu.cn; Bing-
Jian Feng - pj45@gzsums.edu.cn; Hai-De Qin - pj45@gzsums.edu.cn; Zhi-Gang Pan - pj45@gzsums.edu.cn; Guo-
Ping Shen - pj45@gzsums.edu.cn; Li-Xi Huang - pj45@gzsums.edu.cn; Qi-Sheng Feng - pj45@gzsums.edu.cn; Li-
Zhen Chen - pj45@gzsums.edu.cn; Dong-Xin Lin - pj45@gzsums.edu.cn; Yi-Xin Zeng* - yxzeng@gzsums.edu.cn
* Corresponding author    
Abstract
Nasopharyngeal carcinoma (NPC) is characterized by a high prevalence in Southern China,
especially among Cantonese individuals of the Guangdong Province. Epidemiological studies have
suggested that frequent exposure to high levels of nitrosamine from preserved foods such as salted
fish could be a risk factor for NPC. Cytochrome P450 encompasses a family of enzymes that
metabolize carcinogens and CYP2A13, a member of this family, is expressed predominantly in the
respiratory tract with the highest levels in the nasal mucosa. In an effort to test whether a
correlation exists between CYP2A13 genetic polymorphism and the risk of developing NPC, we
sequenced all nine exons and the exon-intron junctions of the CYP2A13 gene in 45 NPC patients.
We identified a total of 21 single nucleotide polymorphism (SNPs), including 7 novel SNPs. The
most frequent functional variant allele was 74A-1757G-3375T-7233G with a haplotype frequency
of 7.8% in the 45 NPC cases. In addition, a stop codon mutation was detected in one case. We then
selected the 3 most frequent SNPs and one stop codon mutation to expand our study to a case-
control analysis within the Cantonese population. A novel haplotype consisting 8 SNPs in introns,
and four additional novel SNPs were identified; but no correlation between CYP2A13 genetic
polymorphism and individual susceptibility to NPC was observed.
Introduction
Nasopharyngeal carcinoma (NPC) is rare in most coun-
tries (incidence below 1/100,000) [1]. However, it has a
high incidence in Southeast Asia, especially in the Guang-
dong province of southern China. This high-risk region is
inhabited by several dialect groups (Cantonese, Hakka,
and Chiu Chau), and each group has been shown to
exhibit variable incidence of NPC. Specifically, the Can-
tonese men and women from the Xijiang river area suffer
the highest rates (10/100,000) that are twice those of their
counterparts in Chiu Chau and trice those of the Hakka
dialect groups [2].
The distinct geographical and ethnic distribution of NPC
seems to be associated with certain environmental and
hereditary factors. Firstly, Epstein-Barr virus (EBV)
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infection is widely recognized as the risk factor of NPC
because of the detection EBV genomes in NPC tumor cells
and elevated serum titers of IgA and IgG antibodies to EBV
early and viral capsid antigens in NPC patients [3-5]. Sec-
ondly, epidemiological studies conducted in diverse pop-
ulations have confirmed that frequent exposure to high
levels of nitrosamine from preserved food such as salted
fish, plum vegetable, preserved prune, fermented beans
and eggs are etiological factors of NPC. Other environ-
mental factors include communal kitchens or kitchen
ranges without chimney, tobacco smoking, occupational
exposures to wood dust and formaldehyde. In addition,
the epidemiological data suggest that higher disease risk is
associated with an earlier age at exposure [6-12].
Although many environment factors were associated with
NPC, only a small proportion of the high-risk population
develops NPC, indicating that there may be important
individual genetic components in the etiology. There is
accumulating evidence of association between genetic
polymorphism of metabolic enzymes and individual var-
iation in cancer susceptibility. In regard to NPC, several
investigations performed in Taiwan and Thailand
reported that individuals homozygous for an allele (c2
allele) of the CYP2E1 have an increased risk of NPC [13-
15]. But no association was observed between genetic pol-
ymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2
and NPC susceptibility [16].
CYP2A13, one of three members of the human CYP2A
gene family, is expressed predominantly in the respiratory
tract with the highest level observed in the nasal mucosa.
The metabolic function of this enzyme was firstly studied
by Su T et al, who demostrated that CYP2A13 exhibits
activity in the activation of hexamethylphosphoramide,
N, N-dimethylaniline, 2'-methoxyacetophenone, N-nitro-
somethylphenylamine, and coumarin 7-hydroxylation.
Specifically, it was noted that this enzyme is highly active
in the metabolic activation of a major tobacco-specific
carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) [17]. Recently, a large number of genetic
polymorphisms of CYP2A13 have been identified in sev-
eral ethnic groups [18-20]. The C/T polymorphism in
exon 5, which leads to Arg257Cys amino acid change, was
the missense mutation of CYP2A13 observed with the
highest frequency. Compared with its wild type, this vari-
ant has significantly reduced activity toward NNK and
other substrates, suggesting that this polymorphism could
provide some protection against xenobiotics to the target
tissues of individuals carrying the 257Cys allele [19]. To
date, there is no report about the relationaship between
CYP2A13 genetic polymorphism and susceptibility to
develop NPC. In this study we first sequenced all nine
exons and exon-intron junctions of the CYP2A13 gene in
45 NPC patients. We, then, performed a case-control
study focused on four CYP2A13 genetic polymorphisms
among Guangdong Cantonese with or without NPC. In
addition, we examined the expression of the CYP2A13
gene in the nasopharyngeal tissue.
Materials and methods
Tissue RNA isolation and RT-PCR
The expression of CYP2A13 in normal Nasopharyngeal
and NPC primary tumors was examined by RT-PCR.
Nasopharyngeal tissues were dissected from biopsies
obtained from patients for diagnostic purposes Informed
consent was obtained from every patient before opera-
tion. Total RNA was extracted with Trizol reagent (Invitro-
gen, CA). About 50 ng of total RNA was reverse
transcribed using Sensiscript Reverse Transcriptase System
(Qiagen, German) and oligod (T) 15 (Bioasia, China).
The PCR amplification of CYP2A13 cDNA sequence was
performed according a previously described method [17].
The expected product is 494 bp in length (923–1416 in
the coding region). A 580 bp cDNA fragment of the
GAPDH gene was amplified as an RNA quality control.
Selection of subjects and genomic DNA preparation
Genomic DNA was isolated from the peripheral blood of
472 incident NPC cases and 709 cancer-free controls by
QIAamp DNA Blood Midi kit (Qiagen, German). All the
cases were recruited from January, 2001 to December,
2003 at the Cancer Center of Sun Yat-sen University and
were histologically confirmed as differentiated non-kerat-
inizing NPC or undifferentiated NPC. Controls were
recruited from individuals presenting at the People's Hos-
pital of Guangdong Province for general check-up. Con-
trols were frequency-matched to the cases by age (± 2
years) and gender. At recruitment, each participant was
personally interviewed to obtain detailed information on
ethnicity and family disease history. All subjects were
Cantonese from the Guangdong province.
Gene sequencing
The sequence of the complete human CYP2A13 gene
described in the GenBank of NCBI (accession number
NG_000766) was used as reference for the design of the
primers. Firstly, the sequence of CYP2A13 was aligned
with that of CYP2A6 and CYP2A7, the alignment results
showed that the sequences of the three genes are highly
homologous. To avoid the amplification of homologous
genes, a pair of CYP2A13 specific primer (8KF and 8KR)
was used to amplify the full-length of CYP2A13 gene that
span from 148 bp upstream of the ATG start codon to 353
bp downstream of the stop codon. The 7971 bp PCR
product was directly submitted to sequencing with primer
for each exon using CEQ 8000 Genetic analysis system
(Beckman Coulter, USA). The long-distance PCR was car-
ried out in a 25 µl reaction mixture containing 200 ng of
genomic DNA, 12.5 µl of 2 × LA-PCR GC buffer I, 4 µl ofJournal of Translational Medicine 2004, 2:24 http://www.translational-medicine.com/content/2/1/24
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2.5 mMol/L dNTPs, 1 µl of 10 µMol/L each primer, and
1.5 unit of LA-Taq DNA polymerase (Takara, Japan). PCR
cycling conditions consisted of an initial denaturation at
94°C for 30 s, followed by 35 cycles of denaturation at
94°C for 15 s, annealing at 62°C for 30 s, and extension
at 68°C for 8 min (plus 10 added seconds each cycle for
extension from the 16th cycle), and then a final extension
at 68°C for 20 min. Primers used for PCR and sequencing
are shown in Table 1.
PCR-RFLP Analysis
Mismatch PCR-RFLP were developed to identify the fre-
quency of 74G>A in exon 1. The polymorphism of 74G>A
is not located in a site of a restriction enzyme. A Nae I
restriction site was created by introducing a G-C change at
the 3'penultimate position of the forward primers for
Exon 1F as described by Hernandez et al [21]. To avoid the
amplification of homologous gene sequences, nested PCR
was used. Firstly, a 315 bp segment was amplified using
primer 8KF and exon 1R. 0.01 µMol of each primer was
mixed with 20 ng DNA in 15 µl reaction buffer containing
200 µMol of each dNTPs and 1 unit of Taq polymerase.
The following thermal condition was used: 5 minutes at
94°C for initial denaturation, and then 30 thermal cycles,
each consisting of a denaturation at 94°C for 30 seconds,
annealing at 66°C for 30 seconds and extension at 72°C
for 30 seconds, followed by a final extension at 72°C for
10 min. The PCR products of the first step were diluted ten
times and then subjected to a second set of 35 cycles PCR
using the mismatched primer exon 1F and Exon 1R. The
reaction mixture and thermal conditions were identical to
the first reaction except for the primer concentration that
was 0.02 µMol for each primer. The 132 bp PCR product
were digested with Nae I (Takara, Japan), the wild-type
allele that carries a Nae I restriction site GCCGGC pro-
duced fragments of 101 bp and 31 bp, while the mutant
amplicon was uncut. For the detection of 3375 C>T in
exon 5, PCR-RFLP analysis which used as previously
described by Zhang et [19]. Briefly, a 332 bp PCR product
was amplified, Hha I (Takara, Japan) cuts the wild-type
allele to give two fragments (99 bp and 233 bp), but does
not cut the 3375C>T allele, thus producing only one band
(332 bp).
Results
Specific antibodies against CYP1A13 are presently not
available, so expression of CYP2A13 was examined by RT-
PCR. RNA was extracted from biopsies of 8 non-cancerous
nasopharynx tissues and 14 NPC tissues. A pair of
CYP2A13 isoform-specific primers was used to amplify a
494 bp fragment. As shown in Fig. 1, RNA expression of
CYP2A13 was detected in 4/8 of non-cancerous nasophar-
ynx tissues and 4/14 NPC tissues. The expression of
CYP2A13 in non-cancerous tissues and NPC was not sig-
nificantly different. Reference GAPDH gene mRNA was
detected in all 21 samples examined. Each assay was per-
formed in duplicate with similar results.
All nine exons and exon-intron junctions of CYP2A13
were screened in 45 NPC patients. The full-length of the
CYP2A13 gene was amplified for direct sequencing. and
no evidence of promiscuous amplification of the
Table 1: Details of the primers used in this study
Primers primer sequence(5'-3'orientation) sequence region Annealing temperature
8KF tgtcctaagctgtgtgggattcagggttgg exon 1 62°C
8KR aaatgggcatgaacgcttttccccttcgt 62°C
Exon 1F cctgactgtgatggtcttgatgtcagtctgcc 66°C
Exon 1R agggagttgtacatctgctctgtgttcagctg 66°C
Exon 2F ctccctcatgaaggtgtccta intron1 exnon2
Intron 2R agagggaagcagagagaggag partial of intron2
Exon 3F cccctgacctctctccac Exon3
Exon 4R actgattttgaggggacactg Exon4
Exon 5F cctggacagatgcctttaactccg Exon5 62°C
Exon 5R tggctttgcacctgcctgcact 62°C
Exon 6F cctctttccacctttggtct Exon 6
Exon 7R gcaggaagctcatggtgtagt Exon 7
Exon 8F catgtctcccaaacttcctgt Exon 8





Note: Primers without annealing temperature were used for sequencing only.Journal of Translational Medicine 2004, 2:24 http://www.translational-medicine.com/content/2/1/24
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homologous genes (CYP2A6 and CYP2A7) was observed.
At least one SNP of the CYP2A13 gene was observed in 11
of 45 sequenced samples. No SNP was detected in other
samples. Sample 7 exhibited most genetic polymorphism
with 13 SNPs.
A total of 21 SNPs of CYP2A13 were identified in 45 NPC
patients, among these, 17 SNPs were observed in introns
and the remaining 4 SNPs in coding regions (cSNPs).
Within the 4 cSNPs we identified two missense mutations
(74G>A and 3375C>T) leading to two respective amino
acid changes (Arg25Gln and Arg257Cy). One nonsense
mutation (578C>T) was detected in exon 2 resulting in a
change from coding for an Arg to a stop codon in codonn
101; a synonymous mutation 1970 A>C was detected in
codon 177. The detailed information on the location, fre-
quency and sample distribution of SNPs is shown in Table
2.
Among the 21 SNPs, the following four: 74G>A
(Arg25Gln), 1757A>G, 3375C>T (Arg257Cys) and
7233T>G were simultaneously observed in homozygote
conditions in one case and heterozygote conditions in five
cases, suggesting a haplotype of 74A-1757G-3375T-
7233G. Haplotype analysis demonstrated that the fre-
quency of this haplotype is 7.8%, and the wide type hap-
lotype constitute 76% of the chromosomes in those cases.
In addition, eight SNPs (281A>G, 396A>G, 419G>A,
424G>A, 441C>T, 672C>A, 6958C>T and 7233T>G)
located in introns were simultaneously observed as heter-
ozygous in 3 samples.
As shown in Table 2, 74G>A and 3375C>T were the most
frequent missense mutation in 45 NPC cases, the geno-
type frequency of these two SNPs were determined in an
expanded samples of 472 NPC cases and 709 healthy con-
trols using Mismatch PCR-RFLP and PCR-RFLP (Fig. 2). In
addition, two fragments including intron 1, exon 2, intron
8 and exon 9 were sequenced in 166 cases and 177 con-
trols to determine the frequency of the stop codon muta-
tion of 578C>T (Arg101OPA) and the most frequent SNP
(7233T>G). Frequency of CYP2A13 genetic
RT-PCR analysis of CYP2A13 mRNA expression in non-cancerous nasopharynx and primary NPC tumors Figure 1
RT-PCR analysis of CYP2A13 mRNA expression in non-cancerous nasopharynx and primary NPC tumors. Eight non-cancerous 
nasopharynx tissues and 14 NPC tissues were detected. The expected product size is 494 bp. Expression of GAPDH (580 bp) 
was amplified as an endogenous control. Lanes 1–8: RT-PCR of RNA from human non-cancerous nasopharynx tissues; lanes 9–
22: RT-PCR of RNA from NPC tissues; M: DL 2000 molecular weight marker.Journal of Translational Medicine 2004, 2:24 http://www.translational-medicine.com/content/2/1/24
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polymorphism obtained by PCR-RFLP and direct
sequencing is shown in Table 3. No significant difference
was observed between NPC cases and controls with regard
to all of the detected sequence variations of CYP2A13.
578C>T changes were not observed in the additional NPC
cases and controls. The linkage of SNPs 281A>G, 396A>G,
419G>A, 424G>A, 441C>T, 672C>A, 6958C>T and
7233T>G was observed in additional five NPC cases and
seven controls, and haplotype analysis proved that the fre-
quency of this haplotype is 2.0%. This is a novel allele of
Table 2: Overview of SNPs of CYP2A13 gene detected in 45 NPC cases
No. Nucleotide change Amino acid change Frequency (%) Sample distribution
No.6,23, 28,38 No.7 No.24 No.25 No.30 No.34 No.36 No.45
1 74 G>A Arg25Gln 7.8 G/A G/A A/A
2 281 A>G Intron 3.3 A/G A/G A/G
3 396 A>G Intron 3.3 A/G A/G A/G
4 419 G>A Intron 3.3 G/A G/A G/A
5 424 G>A Intron 3.3 G/A G/A G/A
6 441 C>T Intron 3.3 C/T C/T C/T
7 578 C>T Arg101OPA 1.1 C/T
8 672 C>A Intron 3.3 C/A C/A C/A
9 742 T>C Intron 1.1 T/C
10 760 T>C Intron 1.1 T/C
11 761 C>T Intron 1.1 C/T
12 867 C>G Intron 1.1 C/G
13 1757 A>G Intron 7.8 A/G A/G G/G
14 1634–1635 ins ACC 133–134 Thr ins /ins ACC
15 1801 G>C Intron 1.1 G/C
16 1970 A>C synonym 1 A/C
17 3375 C>T Arg257Cys 7.8 C/T C/T T/T
18 5530 T>C Intron 1.1 T/C
19 5578 A>C Intron 1.1 A/C
20 6958 C>T Intron 3.3 C/T C/T C/T
21 7233 T>G Intron 12.2 T/G T/G T/G G/G T/G G/G
Notes: The sequence of the complete human CYP2A13 gene described in the GenBank (accession no. NG_000766) was used as a reference 
sequence, with the A of ATG start codon designated as +1.
Table 3: SNP frequency of CYP2A13 gene in NPC cases and controls
Nucleotide change Amino acid change Case Control OR(95% CI)
No % No %
74 G>Aa Arg25Gln 58/472(Het) 12.3 99/709(Het) 14.0 0.86 (0.60–1.24)
4/472(Hom) 0.9 6/709(Hom) 0.9 1.00 (0.24–4.02)
281A>Gc Intron 8/211(Het) 3.8 7/177(Het) 4.0 0.96 (0.31–3.00)
446 T>Cd Intron 0/211 0.0 2/177(Het) 1.1 Fisher exact p = 0.21
578C>T Arg101OPA 1/211(Het) 0.5 0/177 0.0 Fisher exact p = 1.00
3375 C>Tb Arg257Cys 57/472(Het) 12.1 99/709(Het) 14.0 0.85 (0.59–1.22)
4/472(Hom) 0.9 6/709(Hom) 0.9 1.00 (0.24–4.02)
7196 C>T Intron 4/211(Het) 1.9 6/177(Het) 3.4 0.55 (0.13–2.24)
7233 T>G Intron 29/211(Het) 13.7 26/177(Het) 14.7 0.92(0.50–1.70)
3/211(Hom) 1.4 6/177(Hom) 3.4 0.41(0.08–1.88)
Notes: Het: heterozygote; Hom: homozygote; a: Determined by mismatch PCR-RFLP; b: Determined by PCR-RFLP; Other SNPs were determined 
by sequencing; c: Haplotype 281A>G, 396A>G, 419G>A, 424G>A, 441C>T, 672C>A, 6958C>T, 7233T>G was represented by 281A>G in the 
Table; d: three SNPs (446T>C, 447G>A, 454A>T) were simultaneously observed as heterozygote in 2 samples, so they were represented by 
446T>C in the table.Journal of Translational Medicine 2004, 2:24 http://www.translational-medicine.com/content/2/1/24
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CYP2A13 that has not been reported in the Human Cyto-
chrome P450 Allele Nomenclature. In addition, four
novel SNPs (446 T>C, 447 G>A, 454 A>T, and 7196 C>T)
undetected in the previous 45 NPC samples were detected
in the expanded samples.
In conclusion, 25 SNPs were identified in the complete
analysis. Among them, fourteen SNPs had been already
reported while eleven SNPs (424 G>A, 441 C>T, 446 T>C,
447 G>A, 454 A>T, 742 T>C, 760 T>C, 761 C>T, 867 C>G,
6958 C>T, and 7196 C>T) were novel.
Discussion
The expression of CYP2A13 in human tissue was previ-
ously investigated by Su et al [17] who reported that this
gene was transcribed predominantly in the respiratory
tract. In this study, the expression of CYP2A13 was
detected in non-cancerous nasopharynx and NPC tissues.
The expression of CYP2A13 in biopsies of nasopharynx
and the reported enzymatic activity relevant to carcino-
gens metabolism provided a molecular basis for deter-
mining the genetic polymorphism of CYP2A13 in NPC
patients and evaluate possible associations with disease
predisposition.
This is the first report on the genetic polymorphism of
CYP2A13 in NPC patients. A total of 25 SNPs were iden-
tified and, among these, 11 SNPs including 424 G>A, 441
C>T, 446 T>C, 447 G>A, 454 A>T, 742 T>C, 760 T>C, 761
C>T, 867 C>G, 6958 C>T and 7196 C>T were new. In
addition, we described a novel haplotype consisting of 8
SNPs within a non-coding region. Those new alleles and
SNPS have been submitted to the Human Cytochrome
P450 (CYP) Allele Nomenclature Committee.
In 45 NPC samples, the most frequent functional variant
allele of CYP2A13 was found to be 74A-1757G-3375T-
7233G. In the CYP2A13 allele nomenclature http://
Mismatch PCR-RFLP and PCR-RFLP assay for analyzing the 74 G>A and 3375 C>T polymorphisms Figure 2
Mismatch PCR-RFLP and PCR-RFLP assay for analyzing the 74 G>A and 3375 C>T polymorphisms. A: mismatch PCR generats 
a 132 bp amplicon which was digested by Nae I to fragments of 101 bp and 31 bp for the wild-type amplicon, but the 74 G>A 
mutatnt allele is uncut. Lane 4: homozygote (74 AA); Lanes 15,16: heterozygote (74 GA). Other lanes are digestion products of 
wild-type amplicons. B: PCR products of the wild-type 332 bp amplicon containing the 3375 C is digested by Hha I to fragments 
of 233 bp and 99 bp (lanes 1–6, 8–10). Lane 11: digestion of the homozygous 3375 TT mutant allele. Lane 7: digestion of heter-
ozygote (3375 CT).
A.
B.Journal of Translational Medicine 2004, 2:24 http://www.translational-medicine.com/content/2/1/24
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www.imm.ki.se/CYPalleles/cyp2a13.htm, these four
SNPs were included in the allele of CYP2A13*2B. In addi-
tion to these four SNPs, CYP2A13*2B consists of eight
additinal SNPs (-1479T>C; -1429A>G; -1240A>G; -
411G>A; 2211T>C; 6424C>T; 6432C>T; 7571G>C). The
precise phenotype/genotype correlation of this allele has
not been determined. The single mutation of 3375 C>T
(Arg257Cys) was firstly identified by Zhang et al (19) who
then investigated the functional significance of this point
mutation. Compared with the wild-type Arg-257 protein,
the variant Cys-257 protein is characterized by 37% to
56% less enzymatic activity toward all substrates tested.
Since CYP2A13 is highly active in the metabolic activation
of several carcinogens, it was suggested that the reduction
in enzymatic activity observed in variant Cys-257 could
provide some protection against xenobiotic toxicity to tar-
get tissue in individuals who carry this allele. Epidemio-
logical studies related differences in the activity of this
variant to cancer susceptibility. Wang et al reported that
individuals carrying the variant CYP2A13 allele (3375CT
or TT) have a reduced risk of lung adenocarcinoma in rela-
tion to light tobacco smoking (OR = 0.23; 95% CI = 0.08–
0.68), but no protection against lung squamous cell carci-
noma was observed [22]. However, the functional conse-
quences of 74 G>A (Arg25Gln) in exon 1 has not been
investigated yet. In an alignment of P450 sequences http:/
/www.icgeb.org/~p450srv/, codon 25 corresponded to an
Arg for CYP2A13 and to a Gln for CYP2A6 while both
genes code for an Arg in codon 257. It is possible that
Arg25Gln mutation has less effect on the structure and
function of the CYP2A13 protein than Arg257Cys. In
addition, it has not been determined whether other SNPs
in noncoding regions of this haplotype may affect the
transcription of this gene. Therefore, the enzymatic activ-
ity and the expression level of the phenotype associated to
this allele, consequence of Arg25Gln and Arg257Cys dou-
ble mutation should be investigated.
The Arg101OPA mutation represents a null allele, since
the premature stop codon leads to the synthesis of a
severely truncated protein 394 amino acids shorter than
the wild type certainly devoid of catalytic activity. Zhang
et al firstly detected this nonsense mutation in 1 of 31
Chinese individuals and not in other ethnic groups (23
White, 21 Black, 19 Hispanic, and 73 non-Chinese
Asians)[22]. In the presented study, the stop mutation
was detected in only 1 of 211 NPC cases and none of the
177 controls, suggesting it is a rare mutation in the Chi-
nese population. However, Cauffiez recently reported that
this deleterious mutation was the most frequent (5 %)
variant allele of CYP2A13 in the French population, and
that subjects heterozygous for the null allele have an ele-
vated risk of developing small cell lung cancer (OR = 9.9;
95% CI = 1.9–52.2) [23]. This is in contrast with the
Wang's observation of a substantially reduction risk of
developing lung adenocarcinoma in individuals bearing
the less active allele (Arg257Cys) of CYP2A13.
We carried a case-control study in an attempt to character-
ize CYP2A13 genetic polymorphism and NPC susceptibil-
ity. Our results show that frequencies of most of the SNPs
in controls are higher than that of NPC cases, suggesting
that the mutation of this gene could provide slight protec-
tion against NPC. But, among all the investigated SNPs (in
exon or intron), no significant difference was observed to
draw a conclusion.
In summary, the genetic polymorphism of CYP2A13 in
NPC was identified. No strong association was observed
between the variant alleles and risk to develop NPC in the
Cantonese population of southern China.
Abbreviations
NPC, Nasopharyngeal Carcinoma; CYP2A13, Cyto-
chrome P4502A13; CYP2E1, Cytochrome P4502E1; SNP,
Single Nucleotide Polymorphism; RFLP, Restriction Frag-
ment Length Polymorphism; NNK, 4-(methylnitro-
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